Stockscreener 앱 받기
0.9999
1.97%
-0.0201
시장 영업 전:
.99
-0.0099
-0.99%
Alzamend Neuro Inc 주식(ALZN)의 최신 뉴스
ALZN Stock Price, Quote & Chart | ALZAMEND NEURO INC (NASDAQ:ALZN) - ChartMill
Hedge Fund Bets: Can Alzamend Neuro Inc disrupt its industryChart Signals & Consistent Income Trade Recommendations - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Alzamend Neuro in Freefall: A 22% Plunge Shatters $1.93 as Panic Sets In - Bitget
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - Investing News Network
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial - Investing.com
Alzamend’s AL001 meets bioequivalence in phase 2 brain trial By Investing.com - Investing.com Canada
Across 26 brain regions, Alzamend’s lithium drug showed higher levels - Stock Titan
Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency - The Globe and Mail
Alzamend Neuro, Inc. Receives Nasdaq Delisting Notice: SEC Form 8-K Filing March 2026 - Minichart
Alzamend Neuro Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
[8-K] Alzamend Neuro, Inc. Reports Material Event - Stock Titan
Exit Recap: How sensitive is Alzamend Neuro Inc to inflationEarnings Performance Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Quarterly Recap: Will PAVM outperform during market rallies2026 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
Alzamend initiates phase II trial of AL001 in bipolar disorder By Investing.com - Investing.com South Africa
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - Investing News Network
Alzamend Neuro initiates phase II clinical trial of AL001 "lithium in brain" study in patients with bipolar disorder in collaboration with Massachusetts General Hospital - marketscreener.com
Alzamend initiates phase II trial of AL001 in bipolar disorder - Investing.com
Alzamend Neuro Initiates Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study In Patients With Bipolar Disorder In Collaboration With Massachusetts General Hospital - TradingView
Alzamend Neuro, Inc. Q3 2026 Financial Results and SEC 10-Q Filing Overview - Minichart
Alzamend Neuro 10-Q: $0.00M Revenue, $(0.58) EPS Q3; $(1.89) EPS YTD - TradingView
Alzamend Neuro (NASDAQ: ALZN) posts $5.9M loss and warns on going concern - Stock Titan
Alzamend Neuro Establishes ATM Equity Offering Agreement - The Globe and Mail
Is Alzamend Neuro Inc stock a hidden gemEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Alzamend Neuro Inc enters ATM sales agreement to sell up to $3.0 million in common stockSEC filing - marketscreener.com
Alzamend Neuro Launches $3 Million ATM Equity Program With Ascendiant Capital Markets - TradingView
Alzamend Neuro (ALZN) launches $3.0M at-the-market common stock offering - Stock Titan
Alzamend Neuro Inc expected to post a loss of $1.92 a shareEarnings Preview - TradingView
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
ALZN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALZN Should I Buy - Intellectia AI
Alzamend Neuro (ALZN) to Release Quarterly Earnings on Monday - Defense World
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Expands By 51.2% - Defense World
ALZN Technical Analysis & ETF Price Forecast - Intellectia AI
Reverse split and new equity plan in Alzamend Neuro (ALZN) 2026 proxy - Stock Titan
How risky is Alzamend Neuro Inc. stock now2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - mfd.ru
Can Alzamend Neuro Inc. stock hit record highs againMarket Activity Report & Verified Trade Idea Suggestions - mfd.ru
Is Alzamend Neuro Inc. benefiting from interest rate changesEarnings Overview Report & Daily Price Action Insights - mfd.ru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Will Alzamend Neuro Inc. announce a stock splitJuly 2025 Chart Watch & Fast Momentum Entry Tips - mfd.ru
What’s the fair value of Alzamend Neuro Inc. stockQuarterly Earnings Summary & Reliable Entry Point Trade Alerts - mfd.ru
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 0.5% – Here’s Why - Defense World
Earnings Update: What is Alzamend Neuro Incs TAM Total Addressable MarketJuly 2025 Earnings & Technical Pattern Recognition Alerts - baoquankhu1.vn
EPS Watch: What is Alzamend Neuro Incs TAM Total Addressable MarketJuly 2025 Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Community Health Systems Incs ROE strong enough2025 Biggest Moves & Real-Time Market Sentiment Reports - baoquankhu1.vn
Is Alzamend Neuro Inc. stock heavily shortedWeekly Profit Analysis & Daily Profit Maximizing Tips - bollywoodhelpline.com
Aug Sectors: Is Alzamend Neuro Inc stock heavily shortedJuly 2025 News Drivers & Weekly High Return Opportunities - baoquankhu1.vn
Bond Watch: Can Alzamend Neuro Inc stock beat market expectations this quarterQuarterly Growth Report & Capital Protection Trade Alerts - Bộ Nội Vụ
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell? - Defense World
Can Alzamend Neuro Inc. stock beat analyst upgradesJuly 2025 Outlook & Safe Entry Point Identification - ulpravda.ru
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Will Alzamend Neuro Inc. stock attract ESG investorsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Улправда
Will Alzamend Neuro Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Safe Entry Zone Tips - ulpravda.ru
What technical charts say about Alzamend Neuro Inc. stockQuarterly Performance Summary & Reliable Price Breakout Alerts - ulpravda.ru
0.49%
1.47%
자본화:
|
볼륨(24시간):